Go Pro
NASDAQ:REPL

Replimune Group Q1 2027 Earnings Report

Replimune Group logo
$12.96 -0.51 (-3.79%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$12.82 -0.15 (-1.12%)
As of 09:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Replimune Group EPS Results

Actual EPS
-$0.72
Consensus EPS
-$0.69
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Replimune Group Revenue Results

Actual Revenue
N/A
Expected Revenue
$13.60 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Replimune Group Announcement Details

Quarter
Q1 2027
Time
Before Market Opens
Conference Call Date
Friday, August 14, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Replimune Group's Q2 2027 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules

Replimune Group Earnings Headlines

MILLIONAIRE MASTERCLASS INVITE: Altucher
James Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.tc pixel
See More Replimune Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Replimune Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Replimune Group and other key companies, straight to your email.

About Replimune Group

Replimune Group (NASDAQ:REPL) is a biotechnology company focused on developing oncolytic immunotherapies designed to stimulate the immune system to recognize and attack cancer. The company’s approach is based on a proprietary platform that uses genetically engineered herpes simplex virus type 1 (HSV-1) to selectively replicate in tumors and deliver immune-activating payloads.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an investigational oncolytic immunotherapy being evaluated in clinical studies for solid tumors, including melanoma and cutaneous squamous cell carcinoma. The company is also developing additional candidates, including RP2 and RP3, which are designed to incorporate further immune-stimulating mechanisms and potentially address a broader range of cancers.

Founded in 2015 and headquartered in Woburn, Massachusetts, Replimune conducts research and clinical development activities through collaborations and trials involving patients in the United States and other international markets. The company’s leadership has included co-founder and Chief Executive Officer Philip Astley-Sparke, who has experience in biotechnology and oncology-focused drug development.

View Replimune Group Profile